Chest Medicine
Review | Revised definition of pulmonary hypertension and approach to management
12 Apr, 2023 | 13:22h | UTCRelated:
#ESCCongress | 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension.
Pulmonary hypertension: An update of Dx and Tx guidelines – Journal of Family Practice
The physiological basis of pulmonary arterial hypertension – European Respiratory Journal
Topic-Based, Recent Literature Review on Pulmonary Hypertension – Mayo Clinic Proceedings
Review | Managing respiratory muscle weakness during weaning from invasive ventilation
11 Apr, 2023 | 14:12h | UTC
RCT | Targeted hypoglossal nerve stimulation may benefit patients with obstructive sleep apnea
11 Apr, 2023 | 14:07h | UTC
Commentary on Twitter
In this study, proximal targeted hypoglossal nerve responses proved safe and effective in treating sleep apnea and improving sleep architecture and quality of life, while comparing favorably with those in distal hypoglossal nerve stimulation trials. https://t.co/yorNGW9uoi
— JAMA Otolaryngology – Head & Neck Surgery (@JAMAOto) April 6, 2023
M-A | Noninvasive respiratory support after extubation
11 Apr, 2023 | 14:03h | UTC
Review | Pulmonary arterial hypertension in pregnancy
11 Apr, 2023 | 14:06h | UTCPulmonary arterial hypertension in pregnancy – Current Opinion in Cardiology
Review | Evaluation and management of chronic thromboembolic pulmonary hypertension
11 Apr, 2023 | 14:00h | UTCEvaluation and Management of Chronic Thromboembolic Pulmonary Hypertension – Chest
Perspective | ARDS complicating traumatic brain injury. Can opposite strategies converge?
10 Apr, 2023 | 13:39h | UTCAcute respiratory distress syndrome complicating traumatic brain injury. Can opposite strategies converge? – Intensive Care Medicine (free for a limited period)
M-A | High-flow nasal cannula vs. noninvasive positive pressure ventilation in acute hypoxic respiratory failure
10 Apr, 2023 | 13:37h | UTC
Review | Post-COVID syndrome
6 Apr, 2023 | 13:21h | UTCPost-COVID Syndrome – Deutsches Ärzteblatt International
Related:
Long COVID: major findings, mechanisms and recommendations – Nature Reviews Microbiology
ERS/ESICM/ESCMID/ALAT guidelines for the management of severe community-acquired pneumonia
5 Apr, 2023 | 13:45h | UTC
Commentary on Twitter
Management of severe community-acquired pneumonia: @EuroRespSoc @ESICM @ESCMID @ALATorax international guidelines
➡️ evidence-based recommendations for diagnosis, empirical treatment, ABTs
➡️ current knowledge gaps
➡️ recommendations for future research
🖇️ https://t.co/qhe1wlgN9t pic.twitter.com/LMNCbauYfs— Intensive Care Medicine (@yourICM) April 4, 2023
Contrary to prior studies, new research finds no heightened postoperative risk after a recent covid-19 infection
4 Apr, 2023 | 13:54h | UTCCommentaries:
COVID infection within 60 days not tied to adverse postsurgical outcomes – CIDRAP
Adverse Postoperative Outcomes Not Increased With Recent COVID-19 – HealthDay
Related:
ASA and APSF statement on perioperative testing for the COVID-19 virus.
Guideline: SARS‐CoV‐2 infection, COVID‐19 and timing of elective surgery
BJS commission on surgery and perioperative care post-COVID-19.
ASA Guidance: Preoperative testing for COVID-19 is essential, regardless of vaccination.
Position statement: Perioperative management of post-COVID-19 surgical patients.
Bivalent Booster | Observational data suggests no increased cardiovascular risks compared to monovalent vaccine
4 Apr, 2023 | 13:55h | UTCCommentary: Similarly Low Risk of CV Events With Bivalent and Monovalent mRNA Boosters – TCTMD
Commentary on Twitter
In this French study, the risk of cardiovascular events was similar among recipients of the bivalent Pfizer–BioNTech vaccine and the original monovalent vaccine 21 days after the booster dose. https://t.co/FUZbbsn82I pic.twitter.com/ki0FPeutNm
— NEJM (@NEJM) March 29, 2023
M-A | Rapid antigen-based and rapid molecular tests for the detection of SARS-CoV-2
4 Apr, 2023 | 13:52h | UTCRelated:
Interpreting a lateral flow SARS-CoV-2 antigen test – The BMJ
Lateral flow devices maintain detection sensitivity across Alpha, Delta, and Omicron waves
3 Apr, 2023 | 13:53h | UTCSummary: The study assessed the performance of antigen lateral flow devices (LFDs) during the alpha, delta, and omicron waves of the SARS-CoV-2 pandemic in the UK. Researchers aimed to understand LFD performance concerning changes in variant infections, vaccination, viral load, and LFD use, as well as the devices’ ability to detect infectious individuals. Paired LFD and RT-PCR test results were collected from both asymptomatic and symptomatic participants between November 2020 and March 2022.
When compared to RT-PCR testing, the overall LFD sensitivity was 63.2%, and specificity was 99.71%. The sensitivity was higher in symptomatic participants (68.7%) than in asymptomatic participants (52.8%). The study found that increased viral load was independently associated with a higher likelihood of being LFD positive. There was no evidence of a significant difference in LFD sensitivity between the alpha and delta variants, but sensitivity increased during the omicron wave. Vaccination status did not show an independent association with LFD sensitivity.
The study concluded that LFDs can detect most SARS-CoV-2 infections across different viral variants and during vaccine roll-out, contributing to reduced transmission risk. However, LFD performance is lower in asymptomatic individuals, which should be taken into account when designing testing programs.
Invited Commentary: The performance of rapid antigen tests against SARS-CoV-2 variants – The Lancet Infectious Diseases
Related:
Interpreting a lateral flow SARS-CoV-2 antigen test – The BMJ
M-A | Incidence and prognostic role of pleural effusion in patients with pulmonary embolism
31 Mar, 2023 | 13:40h | UTC
Cohort Study | Diffusing capacity strongly predicts all-cause mortality in individuals with COPD
31 Mar, 2023 | 13:31h | UTCDiffusing Capacity and Mortality in Chronic Obstructive Pulmonary Disease – Annals of the American Thoracic Society (link to abstract – $ for full-text)
Commentary: Diffusing capacity ‘strongly predicted’ mortality in COPD patients – Healio (free registration required)
Commentary on Twitter
Diffusing Capacity and Mortality in Chronic Obstructive Pulmonary Disease
🔗 https://t.co/F5Hqkx65hn pic.twitter.com/up0psKKE3i
— Annals of the ATS (@AnnalsATS) January 10, 2023
Updated WHO Guidelines | COVID-19 boosters no longer routinely recommended for low-risk groups
30 Mar, 2023 | 14:33h | UTCSummary: The WHO’s Strategic Advisory Group of Experts on Immunization (SAGE) has revised its COVID-19 vaccination roadmap in light of the Omicron variant and widespread population immunity. The revised roadmap prioritizes protecting those at the highest risk of severe disease and death while maintaining resilient health systems. It introduces cost-effectiveness considerations for vaccinating lower-risk individuals, such as healthy children and adolescents, and presents revised booster dose recommendations.
Priority groups are categorized as high, medium, and low, based on factors like risk of severe disease and death. People in the high-priority group, consisting of older adults, individuals with significant comorbidities or immunocompromising conditions, pregnant persons, and frontline health workers, are advised to receive additional boosters 6 or 12 months after the last dose. The medium priority group, which includes healthy adults without comorbidities and children with comorbidities, is recommended to receive primary series and first booster doses. However, SAGE no longer routinely recommends additional boosters for this group due to limited public health gains.
For the low-priority group, encompassing healthy children and adolescents, vaccination decisions should take into account factors such as disease prevalence and cost-effectiveness. It is important to note that the public health benefits of vaccinating healthy children and adolescents are considerably lower compared to established essential vaccines for children, like rotavirus, measles, and pneumococcal conjugate vaccines.
News Release: SAGE updates COVID-19 vaccination guidance – World Health Organization
Commentaries:
No More COVID-19 Boosters for Healthy People, WHO Experts Recommend – Health Policy Watch
WHO vaccine advisers update COVID vaccine recommendations – CIDRAP
Study suggests no heightened death risk in young people with mRNA vaccines, but ChAdOx1 nCoV-19 vaccine linked to female cardiac deaths
30 Mar, 2023 | 14:28h | UTC
Commentary from the author on Twitter (thread – click for more)
Our latest @NatureComms research: Risk of death following COVID-19 vaccination or positive SARS-CoV-2 test in young people in England. Led by @Vnafilyan @kamleshkhunti @IsobelLWard et al. https://t.co/oxNdgEAflQ (1/3)
— Prof Amitava Banerjee💙 (@amibanerjee1) March 28, 2023
Review | Supplemental oxygen and noninvasive ventilation
29 Mar, 2023 | 13:18h | UTCSupplemental oxygen and noninvasive ventilation – European Respiratory Review
Consensus Paper | Diagnosis and treatment of anticancer drug-induced interstitial lung disease
29 Mar, 2023 | 13:04h | UTC
M-A | Risk factors associated with post−COVID-19 condition
28 Mar, 2023 | 15:07h | UTCCommentary:
Meta-analysis reveals risk, protective factors for long COVID – CIDRAP
Long Covid: University of East Anglia study finds women more likely affected – BBC
People who catch Omicron are less likely to get Long Covid
28 Mar, 2023 | 15:04h | UTCPeople who catch Omicron are less likely to get Long Covid – Science
M-A | The natural history of untreated pulmonary tuberculosis in adults
28 Mar, 2023 | 14:42h | UTCThe natural history of untreated pulmonary tuberculosis in adults: a systematic review and meta-analysis – The Lancet Respiratory Medicine (free registration required)
Commentary from the author on Twitter
https://twitter.com/bianca_sossen/status/1639143776613482497
Pulmonary hypertension | An update of Dx and Tx guidelines
28 Mar, 2023 | 14:32h | UTCPulmonary hypertension: An update of Dx and Tx guidelines – Journal of Family Practice
M-A | Examining shorter antibiotic treatment durations for community acquired pneumonia in adults
27 Mar, 2023 | 13:29h | UTCSummary: The systematic review and duration-effect meta-analysis included nine randomized trials with a total of 2,399 patients, analyzing antibiotic treatment durations for community-acquired pneumonia (CAP) in adults. The primary outcome was clinical improvement on day 15, with secondary outcomes including all-cause mortality, serious adverse events, and clinical improvement on day 30.
The study found that shorter treatment durations (3–9 days) were likely to be non-inferior to the standard 10-day treatment, and no significant difference in all-cause mortality or serious adverse events was observed. The study suggests that a 3–5 day treatment duration likely offers the optimal balance between efficacy and treatment burden if patients are clinically stable. However, the results are limited by the small number of included studies, the overall moderate-to-high risk of bias, and the varying severity of CAP among patients in the studies. Therefore, further research focusing on the shorter duration range is required.
Related: